{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:20:19Z","timestamp":1785320419101,"version":"3.55.0"},"reference-count":13,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Parkinson\u2019s Disease"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:p>Alpha-synuclein is a normal protein, but misfolded forms in the cerebrospinal fluid can be detected using the alpha-synuclein seed amplification assay (\u03b1Syn-SAA), a potential biomarker for Parkinson's disease (PD). Some experts consider this assay a \u2018game changer\u2019 for redefining and reclassifying PD. In this article, we, three individuals with PD, share our perspective on the suitability of \u03b1Syn-SAA as the basis for a new classification and staging system for PD. We also discuss other biomarkers and their relevance to those with PD, drawing on our research and the scientific background of two authors. We aim to clarify complex media reports and study findings for the PD community. We argue that while \u03b1Syn-SAA can identify the presence of pathology, it cannot explain the underlying cause for such pathology or predict the progression of PD. Given the varied biological pathways leading to PD, using \u03b1Syn-SAA as a unified biological definition for a new classification system is premature. Further research is needed before it can serve as the foundation for defining and staging Parkinson's disease. Although \u03b1Syn-SAA has its place, like the DAT scan, it should be seen as a tool for confirming diagnoses rather than defining them.<\/jats:p>","DOI":"10.1177\/1877718x251315651","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:20:17Z","timestamp":1738887617000},"page":"953-956","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["A perspective of persons with Parkinson's disease on the contribution of alpha-synuclein seed amplification assay biomarker to the diagnosis of Parkinson's disease"],"prefix":"10.1177","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9481-0128","authenticated-orcid":false,"given":"Susanne","family":"Bowen","sequence":"first","affiliation":[{"name":"Independent Researcher, Westfield, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0046-9776","authenticated-orcid":false,"given":"David","family":"Blacker","sequence":"additional","affiliation":[{"name":"Perron Institute for Neurological and Translational Science, Nedlands, Western Australia. University of Western Australia, Nedlands, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4908-1951","authenticated-orcid":false,"given":"Richard","family":"Prettyman","sequence":"additional","affiliation":[{"name":"Retired (Formerly Consultant Old Age Psychiatrist, Leicestershire Partnership NHS Trust, Leicester, UK"},{"name":"Honorary Associate Professor in Health Sciences, University of Leicester UK, Leicester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00218-X"},{"key":"e_1_3_3_3_2","unstructured":"Michael J. Fox Foundation. Michael J. Fox Foundation Funds Projects to Speed Development of Quantitative Biomarkers for Parkinson\u2019s Disease https:\/\/www.michaeljfox.org\/publication\/michael-j-fox-foundation-funds-projects-speed-development-quantitative-biomarkers (2024 accessed 11 October 2024)."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48961-3"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26923"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab431"},{"key":"e_1_3_3_7_2","unstructured":"Michael J. Fox Foundation. Breaking News: Parkinson's Disease Biomarker Found https:\/\/www.michaeljfox.org\/news\/breaking-news-parkinsons-disease-biomarker-found (2023 accessed 11 October 2024)."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.2054"},{"key":"e_1_3_3_9_2","unstructured":"Cardoso F Trenkwalder C. A summary of the MDS \u2018Statement of the MDS on Biological Definition Staging and Classification of Parkinson\u2019s Disease\u2019. Moving Along 2024; 28: https:\/\/www.movementdisorders.org\/Moving-Along\/2024-issue-1\/Statement-of-the-MDS-on-Biological-Definition-Staging-and-Classification-of-PD.htm."},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00109-6"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00030-2"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2023.105926"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-022-00286-1"},{"key":"e_1_3_3_14_2","unstructured":"Parkinson\u2019s Foundation. PD GENEration: Mapping the Future of Parkinson's Disease. https:\/\/www.parkinson.org\/advancing-research\/our-research\/pdgeneration# (2024 accessed 11 October 2024)."}],"container-title":["Journal of Parkinson\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1877718X251315651","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1877718X251315651","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1877718X251315651","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:51:13Z","timestamp":1777589473000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1877718X251315651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1177\/1877718X251315651"],"URL":"https:\/\/doi.org\/10.1177\/1877718x251315651","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]}}}